Osiris trumpets patchy Prochymal heart data, and extend trial duration
This article was originally published in Clinica
Executive Summary
Osiris's off-the-shelf stem cell treatment Prochymal (remestemcel-L) has shown some early promise in preventing heart failure in a Phase II trial in heart attack patients, the company says. But although the trial, with some 220 patients, is one of the largest stem cell studies ever undertaken, the top-line data released by the company are patchy and no figures for the primary endpoint measure of left ventricular end systolic volume have yet been given, clouding the true picture of the product's efficacy in the study until the full data are released.
You may also be interested in...
The Shifting Sands Of Biopharma R&D
A year is a long time in biopharma. Pharmaprojects’ annual pipeline review finds changes in the therapeutic spread of drug candidates and a reordering of the top R&D companies, as Chinese firms made their presence felt all the more over the past 12 months.
Nine Pivotal Studies To Look Out For In 2024
While not expected to be quite so busy as previous years, 2024 will still see many pivotal clinical trial readouts that should create a splash. Here are nine (plus a few extras) that have caught attention for one reason or another, e.g., for being the first readout for a novel drug class, having the potential to take a product in a new lucrative direction, for maybe being able to succeed where a rival has already failed or even for having been a long time coming.
10 Pivotal Studies To Look Out For In 2024
While not expected to be quite so busy as previous years, 2024 will still see many pivotal clinical trial readouts that should create a splash. Here are ten (plus a few extras) that have caught Scrip’s eye for one reason or another, eg, for being the first readout for a novel drug class, having the potential to take a product in a new lucrative direction, for maybe being able to succeed where a rival has already failed or even for having been a long time coming.